Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Caldera Medical Announces FDA Clearance Of Novel Treatment For Pelvic Organ Prolapse
Caldera Medical, Inc. announced that it has received FDA clearance and CE Mark certification for the Ascend Pelvic Floor Repair System with Apical Support, a novel treatment for female pelvic organ prolapse. Ascend® is the latest addition to the Caldera Medical family of products designed to treat female stress urinary incontinence (SUI) and pelvic organ prolapse (POP). Caldera"s product line includes the Desara® Sling System, a universal sling that allows surgeons their choice of multiple surgical approaches by utilizing reusable instrumentation. Caldera is the only U.S. company offering this unique solution, which benefits surgeons, hospitals, and the environment.
generic viagra online
National Survey: Americans Fear Paying For Cancer Treatment As Much As Dying Of The Disease
The Community Oncology Alliance (COA) announced results of a national survey that reveals the inability to pay for cancer care is among Americans" top fears about the disease. Seven out of ten report being very concerned about paying for cancer treatment if they developed the disease (69%), the same proportion who are very concerned about dying of it (68%). Only the cancer consequences of having a poor quality of life (75%) and being in pain (72%) evoke slightly more concern.
News of the day
Kefir, Although Rich In Probiotics, Didn't Prevent Diarrhea In Children Using Antibiotics
Kefir, one of the world"s oldest "health" drinks, did little to prevent diarrhea in young children being treated with antibiotics, say researchers at Georgetown University Medical Center (GUMC), who tested the drink in a unique and rigorous double-blind clinical trial.
Health Insurance

Progression Of Skeletal Muscle Disorder Slowed By Vaccine

A potential vaccine for Alzheimer"s disease also has been shown in mice to slow the weakening of muscles associated with inclusion body myositis, a disorder that affects the elderly. The finding brings new hope for IBM patients with weakness, inflammation or atrophy of muscles in their fingers, wrists, forearms or quadriceps. There is no cure for IBM, nor is there an effective treatment, according to the National Institutes of Health. "The immunization wasn"t a complete fix, but it significantly slowed the deterioration of motor function in our IBM mice," said Frank LaFerla, director of UC Irvine"s Institute for Brain Aging and Dementia. "I hope our discovery leads to clinical trials and, eventually, a vaccine for people suffering from or at risk for IBM." Study results appear in The Journal of Neuroscience. LaFerla and assistant project scientist Masashi Kitazawa tested the vaccine on 1-year-old mice with high levels of a protein called beta amyloid in their skeletal muscle tissue - a characteristic feature of IBM. After three months of treatment, the mice were producing antibodies against beta amyloid and had less of the protein in their muscles. Levels of oligomeric beta amyloid - a more toxic form - also were reduced. "It appears the antibodies helped remove beta amyloid or blocked its accumulation in muscle cells so they could stay healthy longer," Kitazawa said. Immunotherapy approaches such as vaccination are being extensively studied for Alzheimer"s in humans. In that disease, beta amyloid accumulates in the brain and leads to the creation of senile plaques, one of two signature Alzheimer"s lesions. Although immunotherapy has shown some benefit in human clinical trials, there are significant safety concerns. For example, about 6 percent of people develop encephalitis, or brain inflammation. LaFerla thinks it"s unlikely IBM patients would develop encephalitis: "With IBM, brain integrity is not compromised like it is with Alzheimer"s. We should be cautious, but there"s little reason to assume IBM patients would have the same problem." UCI scientists Vitaly Vasilevko and David Cribbs also worked on this study, supported by the NIH. Jennifer Fitzenberger University of California - Irvine


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009